Quanta Therapeutics announced the completion of a Series D extension financing round that provides funding through key clinical data readouts. The company presented positive clinical combination data for its lead program QTX3034 in KRAS G12D-mutant colorectal cancer at ESMO Congress 2026. Quanta is advancing QTX6255, a potential best-in-class pan-KRAS inhibitor, toward an IND filing in Q4 2026 with Phase 1 trials anticipated in early 2027. The extension round strengthens the company's cash position to support these critical development milestones.
Who to call at Quanta Therapeutics, and when
A new round usually means Quanta Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Quanta Therapeutics raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Quanta Therapeutics, from your own LinkedIn network
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Quanta Therapeutics
About
Quanta Therapeutics is a privately held, clinical-stage biopharmaceutical company leading the development of innovative therapeutics for RAS-driven cancers. The company is advancing oral KRAS inhibitors, including QTX3034 (a G12D-preferring multi-KRAS inhibitor) and QTX6255 (a potential best-in-class pan-KRAS inhibitor). Quanta is focused on addressing high unmet needs in cancer treatment through potent, direct KRAS inhibition combined with other targeted therapies.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Quanta Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
